NCT03827876PHASE4Recruiting
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Psoriasis Treatment Center of Central New Jersey
Start Date
1/16/2019
Completion Date
12/15/2019
Summary
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Detailed Description
30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar® once daily for 4 weeks followed by QOD for 12 weeks.
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
* Male or female adult ≥ 18 years of age;
* Diagnosis of chronic plaque-type
* Patient with 2-10% BSA
* Physician Global Assessment of 2 or greater
* Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks
Exclusion Criteria:
* ˂2 or \>10% BSA
* PGA \<2
* Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \<24weeks
Interventions
DRUG
Enstilar 0.005%-0.064% Topical Foam
Conditions
Psoriasis
Locations
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey 08520
United States